KR890007724A - 약물-모노클로날 항체 결합체 - Google Patents
약물-모노클로날 항체 결합체 Download PDFInfo
- Publication number
- KR890007724A KR890007724A KR1019880015383A KR880015383A KR890007724A KR 890007724 A KR890007724 A KR 890007724A KR 1019880015383 A KR1019880015383 A KR 1019880015383A KR 880015383 A KR880015383 A KR 880015383A KR 890007724 A KR890007724 A KR 890007724A
- Authority
- KR
- South Korea
- Prior art keywords
- drug
- group
- substituted
- monoclonal antibody
- carbon atoms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 MMC를 그의 상응하는 전구약물로부터 방출시키는 경로를 도시한 도면,
제2도는 본 발명에 따른 대표적인 약물-모노클로날 항체 결합체의 합성을 도시한 도면.
제3도는 본 발명에 따른 전구약물로서의 유도체들의 HPLC비교 분석 결과를 도시한 도면.
Claims (6)
- 다음의 일반식을 갖는 항종양 약물-모노클로날 항체 결합체:상기 일반식 중, D는 항종양 약물 부분으로서 그의 기본 골격에 일반식R1NH-로 나타내지는 1차 아미노기, 일반식 R1R2N-으로 나타내지는 2차 아미노기, 및 일반식 R10-로 나타내지는 알코올기 중에서 유도된 화학 반응성 관능기를 부속적으로 가지고, 이에 의해 약물의 기본 골격이 디술파이드 벤질옥시카르보닐기에 결합되며; R1은 D가 1차 아미노기, 2차 아미노기, 및 알코올기중에서 유도되는 경우 상기 약물의 기본 골격을 이루며, 여기서 2차 아미노기의 경우, R1및R2는 독립적이고; R2는 R1과 R2가 독립적인 경우, 탄소원자를 1-3개 갖는 1-3개의 알콕시기와 1-3개의 할로기 중에서 선택된 치환체로 치환되거나 치환되지 않고, 측쇄를 갖거나 직쇄인 탄소원자1-10개의 알킬기; 탄소원자를 1-3개 갖는 1-개의 알킬기, 탄소원자를 1-3개 갖는 1-3개의 알콕시기, 및 1-3개의 할로기 중에서 선택된 치환체로 치환되거나 치환되지 않은 페닐; 및 치환되거나 치환되지 않은 페닐알킬로서 이때 페닐부분은 치환되는 경우, 상기 치환페닐의 경우 정의된 바와 같이 치환되고 알킬 부분은 탄소원자를 1-3개 갖는 폴리알킬렌기인 페닐알킬 중에서 선택되며; R1과 R2는 2차 아민으로부터 유도된 관능기에서 함께 취해질 경우, 상기 2차 아미노기를 구성하는 질소원자에 화학적으로 결합된 2가지를 가지며 약물 부분 D의 기본 골격을 나타내고; R3과 R4는 H 및 탄소원자를 1-3개 갖는 알콕시기 및 1-3개의 할로기 중에서 선택된 치환체로 치환되거나 치환되지 않고, 측쇄를 갖거나 직쇄인 탄소원자 1-10개를 갖는 알킬기; 탄소원자를 1-3개 갖는 1-3개의 알킬기, 탄소원자를 1-3개 갖는 1-3개의 알콕시기 및 1-3개의 할로기 중에서 선택된 치환체로 치환되거나 치환되지 않는 페닐; 및 치환되거나 치환되지 않은 페닐알킬로서, 이때 페닐 부분은 치환되는 경우, 상기 치환 페닐의 경우 정의된 바와 같이 치환되고 알킬 부분은 1-3개의탄소원자를 갖는 폴리알킬렌기인 페닐알킬 중에서 독립적으로 선택되며; m은 1에서 10까지의 정수중 하나이고; Ab는 부속 아미노기를 갖는 모노클로날 항체를 나타내며; 벤질카르바메이트 부분의 페닐 고리상의기의 치환 방향은 오르토-및 파라위치 중에서 선택된다.
- 제1항에 있어서, 약물 부분 D가, 1차 아민 함유 약물 및 2차 아민 함유 약물 중에서 선택됨을 특징으로 하는 항종양 약물-모노클로날 항체 결합체.
- 제2항에 있어서, 약물 부분D가 미토마이신-C, 미토마이신-A, 다우노마이신, 아드리아마이신, 아미노프테린, 악티노마이신, 블레오마이신 및 이들의 유도체 중에서 선택됨을 특징으로 하는 항종양 약물-모노클로날 항체 결합체.
- 제1항에 있어서, 약물 부분D가 알코올기 함유 약물인 것이 특징인 항종양 약물-모노클로날 항체 결합체.
- 제4항에 있어서, 약물 부분D가 에토포시드인 것이 특징인 항종양 약물-모노클로날 항체 결합체.
- (a) 제1항에 따른 항종양 약물-모노클로날 항체 결합체의 항종양 유효량을 포유동물에 투여하고, (b) (a)단계로부터의 항종양 약물-모노클로날 항체 결합체를 내인성 환원 조건에 접하게 하여 (c) 항종양 약물-모노클로날 항체를 환원적으로 분해시켜 이 결합체로부터 유리 약물을 방출시키는 단계로 이루어짐을 특징으로하는, NADH, NADPH 및 글로타치온중 적어도 하나를 포함하는 내인성 환원제를 높은 수준으로 갖는 포유동물의 종양세포 부위에, 일반식 R1NH-로 나타내지는 1차 아미노기, 일반식 R1R2N-으로 나타내지는 2차 아미노기, 일반식 R1O로 나타내지는 알코올기(이때 R1및 R2는 상기 정의된 바와 같음)중에서 선택된 화학 반응성 관능기를 그의 기본 골격에 부수적으로 갖는 활성 항종양 약물을 전달하는 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US124,313 | 1987-11-23 | ||
US07/124,313 US4952394A (en) | 1987-11-23 | 1987-11-23 | Drug-monoclonal antibody conjugates |
US124.313 | 1987-11-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR890007724A true KR890007724A (ko) | 1989-07-05 |
KR910005887B1 KR910005887B1 (ko) | 1991-08-06 |
Family
ID=22414122
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019880015383A KR910005887B1 (ko) | 1987-11-23 | 1988-11-22 | 약물-모노클로날 항체 결합체 |
Country Status (16)
Country | Link |
---|---|
US (1) | US4952394A (ko) |
EP (1) | EP0317957B1 (ko) |
JP (1) | JPH02111731A (ko) |
KR (1) | KR910005887B1 (ko) |
AT (1) | ATE81986T1 (ko) |
AU (1) | AU617380B2 (ko) |
CA (1) | CA1303524C (ko) |
DE (1) | DE3875700T2 (ko) |
DK (1) | DK651088A (ko) |
FI (1) | FI885361A (ko) |
GR (1) | GR3006211T3 (ko) |
IL (1) | IL88428A0 (ko) |
NO (1) | NO169958C (ko) |
NZ (1) | NZ226955A (ko) |
PT (1) | PT89062B (ko) |
ZA (1) | ZA886811B (ko) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5149782A (en) * | 1988-08-19 | 1992-09-22 | Tanox Biosystems, Inc. | Molecular conjugates containing cell membrane-blending agents |
US5171563A (en) * | 1988-09-30 | 1992-12-15 | Neorx Corporation | Cleavable linkers for the reduction of non-target organ retention of immunoconjugates |
US5155210A (en) * | 1990-09-11 | 1992-10-13 | Brunswick Corporation | Methods of conjugating actinomycin d |
EP0510132B1 (en) * | 1990-09-28 | 1997-05-14 | Neorx Corporation | Polymeric carriers for release of covalently linked agents |
US5776458A (en) * | 1990-12-05 | 1998-07-07 | Pharmacia & Upjohn S.P.A. | Anthracycline-conjugates |
FR2676058B1 (fr) * | 1991-04-30 | 1994-02-25 | Hoechst Lab | Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers. |
ATE412769T1 (de) * | 1994-04-05 | 2008-11-15 | Morre D James | Nadh-oxidase als zielmolekül in diagnose und therapie |
US20030119724A1 (en) * | 1995-11-22 | 2003-06-26 | Ts`O Paul O.P. | Ligands to enhance cellular uptake of biomolecules |
EP0932390A1 (en) * | 1996-10-11 | 1999-08-04 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method |
US6207805B1 (en) | 1997-07-18 | 2001-03-27 | University Of Iowa Research Foundation | Prostate cell surface antigen-specific antibodies |
US7157418B1 (en) | 1998-07-22 | 2007-01-02 | Osprey Pharmaceuticals, Ltd. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
US20030215421A1 (en) * | 1999-07-21 | 2003-11-20 | Mcdonald John R. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
US6299860B1 (en) * | 1998-10-15 | 2001-10-09 | Fluoro Probe, Inc. | Method for viewing diseased tissue located within a body cavity |
US6652836B2 (en) | 1998-10-15 | 2003-11-25 | Fluoroprobe, Inc. | Method for viewing tumor tissue located within a body cavity |
US7303760B2 (en) | 1999-04-23 | 2007-12-04 | Alza Corporation | Method for treating multi-drug resistant tumors |
US7238368B2 (en) | 1999-04-23 | 2007-07-03 | Alza Corporation | Releasable linkage and compositions containing same |
MXPA01010750A (es) * | 1999-04-23 | 2003-08-20 | Alza Corp | Conjugado que tiene un enlace dividible para utilizarse en un liposoma. |
NZ514990A (en) * | 1999-04-23 | 2004-01-30 | Alza Corp | Releasable linkage and compositions containing same |
US7112337B2 (en) | 1999-04-23 | 2006-09-26 | Alza Corporation | Liposome composition for delivery of nucleic acid |
CN1110322C (zh) * | 1999-07-21 | 2003-06-04 | 中国医学科学院医药生物技术研究所 | 单克隆抗体Fab'-平阳霉素偶联物及其抗肿瘤作用 |
AU2001227679A1 (en) * | 2000-02-25 | 2001-09-03 | General Atomics | Mutant nucleic binding enzymes and use thereof in diagnostic, detection and purification methods |
AU2001250898A1 (en) * | 2000-03-17 | 2001-10-03 | The Salk Institute For Biological Studies | Compositions associated with complex formation |
US6610504B1 (en) | 2000-04-10 | 2003-08-26 | General Atomics | Methods of determining SAM-dependent methyltransferase activity using a mutant SAH hydrolase |
EP1282714A2 (en) * | 2000-05-10 | 2003-02-12 | Bristol-Myers Squibb Company | Modified inosine 5'-monophosphate dehydrogenase polypeptides and uses thereof |
WO2002043771A2 (en) | 2000-12-01 | 2002-06-06 | Cell Works Inc. | Conjugates of glycosylated/galactosylated peptide |
WO2002092771A2 (en) | 2001-05-11 | 2002-11-21 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
KR20030033007A (ko) * | 2001-05-31 | 2003-04-26 | 코울터 파머수티컬, 인코포레이티드 | 세포독소, 약물전구체, 링커 및 이에 유용한 안정화제 |
US7053188B2 (en) | 2002-02-22 | 2006-05-30 | Purdue Research Foundation | Monoclonal antibodies specific for neoplasia-specific NADH:disulfide reductase |
US7384760B2 (en) * | 2004-04-30 | 2008-06-10 | General Atomics | Methods for assaying inhibitors of S-adenosylhomocysteine (SAH) hydrolase and S-adenosylmethionine (SAM)-dependent methyltransferase |
CA2564076C (en) * | 2004-05-19 | 2014-02-18 | Medarex, Inc. | Chemical linkers and conjugates thereof |
US7691962B2 (en) * | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
US7541330B2 (en) * | 2004-06-15 | 2009-06-02 | Kosan Biosciences Incorporated | Conjugates with reduced adverse systemic effects |
AU2005281359A1 (en) * | 2004-08-26 | 2006-03-16 | Apparao Satyam | Prodrugs and codrugs containing novel bio-cleavable disulfide linkers |
CN101124249B (zh) * | 2005-02-18 | 2011-06-29 | 米德列斯公司 | 抗前列腺特异性膜抗原(psma)的人单克隆抗体 |
US7714016B2 (en) * | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
BRPI0617546A2 (pt) * | 2005-09-26 | 2011-07-26 | Medarex Inc | conjugado de fÁrmaco-anticorpo, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula de tumor, mÉtodo para retardar ou interromper o crescimento de um tumor em um sujeito mamÍfero e composto |
CA2627046C (en) | 2005-10-26 | 2015-09-15 | Medarex, Inc. | Methods and compounds for preparing cc-1065 analogs |
CA2627190A1 (en) | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
TWI412367B (zh) | 2006-12-28 | 2013-10-21 | Medarex Llc | 化學鏈接劑與可裂解基質以及其之綴合物 |
MX2009007987A (es) | 2007-01-25 | 2010-03-01 | Dana Farber Cancer Inst Inc | Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante. |
TW200900059A (en) * | 2007-02-21 | 2009-01-01 | Medarex Inc | Chemical linkers with single amino acids and conjugates thereof |
US9023356B2 (en) | 2007-03-15 | 2015-05-05 | Ludwig Institute For Cancer Research Ltd | Treatment method using EGFR antibodies and SRC inhibitors and related formulations |
EP2164875A4 (en) | 2007-05-24 | 2011-11-30 | Us Dept Veterans Affairs | INTRANUCLEAR PROTEIN TRANSDUCTION THROUGH A NUCLEOSIDE SALVAGE PATHWAY |
JP5532486B2 (ja) | 2007-08-14 | 2014-06-25 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | Egf受容体を標的とするモノクローナル抗体175ならびにその誘導体および用途 |
CA3128656A1 (en) | 2007-08-22 | 2009-02-26 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
CA2699912A1 (en) * | 2007-09-19 | 2009-03-26 | Oncofluor, Inc. | Method for imaging and treating organs and tissues |
KR101666631B1 (ko) | 2008-05-27 | 2016-10-17 | 젠자임 코포레이션 | 알파-멜라노사이트 자극 호르몬의 펩티드 유사체 |
NZ602824A (en) | 2008-12-05 | 2014-05-30 | Abraxis Bioscience Llc | Sparc binding peptides and uses thereof |
EP2385955B1 (en) | 2009-01-12 | 2020-08-12 | CytomX Therapeutics, Inc. | Modified antibody compositions, methods of making and using thereof |
WO2010096394A2 (en) | 2009-02-17 | 2010-08-26 | Redwood Biosciences, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
AU2010215761B2 (en) | 2009-02-23 | 2017-04-06 | Cytomx Therapeutics, Inc | Proproteins and methods of use thereof |
US9155801B2 (en) | 2009-05-28 | 2015-10-13 | The United States Government As Represented By The Department Of Veterans Affairs | Amino acid sequences which enhance peptide conjugate solubility |
US8871744B2 (en) | 2010-07-21 | 2014-10-28 | B & G Partyers, LLC | Compounds and methods for selectively targeting tumor-associated mucins |
GB201012410D0 (en) | 2010-07-23 | 2010-09-08 | Medical Res Council | Intracellular immunity |
AU2012205301B2 (en) | 2011-01-14 | 2017-01-05 | Redwood Bioscience, Inc. | Aldehyde-tagged immunoglobulin polypeptides and method of use thereof |
GB201202268D0 (en) | 2012-02-09 | 2012-03-28 | Medical Res Council | Intracellular immunity |
JP6133431B2 (ja) | 2012-11-24 | 2017-05-24 | ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. | 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用 |
US10464955B2 (en) | 2014-02-28 | 2019-11-05 | Hangzhou Dac Biotech Co., Ltd. | Charged linkers and their uses for conjugation |
JP6921743B2 (ja) | 2014-11-05 | 2021-08-18 | ナンヤン テクノロジカル ユニヴァーシティー | 安定化かつ自律性抗体vhドメイン |
AU2015242213A1 (en) | 2015-07-12 | 2018-03-08 | Hangzhou Dac Biotech Co., Ltd | Bridge linkers for conjugation of cell-binding molecules |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
AU2017257504A1 (en) | 2016-04-26 | 2018-10-25 | R.P. Scherer Technologies, Llc | Antibody conjugates and methods of making and using the same |
CA3027960C (en) | 2016-06-15 | 2022-06-14 | Yale University | Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors |
US20190330317A1 (en) | 2016-06-15 | 2019-10-31 | Yale University | Anti-guanosine antibody as a molecular delivery vehicle |
KR20220147720A (ko) | 2016-11-14 | 2022-11-03 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용 |
WO2019152806A1 (en) | 2018-02-01 | 2019-08-08 | Yale University | Compositions and methods for enhancing nuclear translocation |
WO2022013613A2 (en) | 2020-07-17 | 2022-01-20 | Onena Medicines S.L. | Antibodies against lefty proteins |
EP4079327A1 (en) * | 2021-04-22 | 2022-10-26 | Centaurus Polytherapeutics | Payloads for drug-conjugates and their use for treating cancer |
WO2023010060A2 (en) | 2021-07-27 | 2023-02-02 | Novab, Inc. | Engineered vlrb antibodies with immune effector functions |
WO2023056450A1 (en) | 2021-09-30 | 2023-04-06 | Yale University | Compositions and methods for the treatment of autosomal dominant polycystic kidney disease and other diseases having upregulated mtor activity |
WO2024050524A1 (en) | 2022-09-01 | 2024-03-07 | University Of Georgia Research Foundation, Inc. | Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death |
WO2024064752A2 (en) | 2022-09-20 | 2024-03-28 | Yale University | Compositions of wet adhesives derived from vibrio cholerae biofilm adhesins and methods thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4003792A (en) * | 1967-07-01 | 1977-01-18 | Miles Laboratories, Inc. | Conjugates of acid polysaccharides and complex organic substances |
AU8762982A (en) * | 1981-07-02 | 1983-02-02 | Walton, A.G. | Glycosaminoglycan drug complexes |
US4671958A (en) * | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
JPH0651643B2 (ja) * | 1983-01-19 | 1994-07-06 | 帝人株式会社 | 殺細胞性修飾免疫グロブリン及びその製造方法 |
US4625014A (en) * | 1984-07-10 | 1986-11-25 | Dana-Farber Cancer Institute, Inc. | Cell-delivery agent |
DE3684887D1 (de) * | 1985-11-29 | 1992-05-21 | Biomatrix Inc | Arzneistoffabgabesysteme auf basis von hyaluronan, dessen derivaten und salzen sowie verfahren zu deren herstellung. |
GB8603537D0 (en) * | 1986-02-13 | 1986-03-19 | Parker D | Conjugate compound |
-
1987
- 1987-11-23 US US07/124,313 patent/US4952394A/en not_active Expired - Fee Related
-
1988
- 1988-09-13 ZA ZA886811A patent/ZA886811B/xx unknown
- 1988-11-10 CA CA000582744A patent/CA1303524C/en not_active Expired - Fee Related
- 1988-11-14 NZ NZ226955A patent/NZ226955A/en unknown
- 1988-11-18 FI FI885361A patent/FI885361A/fi not_active IP Right Cessation
- 1988-11-21 IL IL88428A patent/IL88428A0/xx unknown
- 1988-11-22 DK DK651088A patent/DK651088A/da not_active Application Discontinuation
- 1988-11-22 EP EP88119419A patent/EP0317957B1/en not_active Expired - Lifetime
- 1988-11-22 AT AT88119419T patent/ATE81986T1/de not_active IP Right Cessation
- 1988-11-22 DE DE8888119419T patent/DE3875700T2/de not_active Expired - Fee Related
- 1988-11-22 NO NO885199A patent/NO169958C/no unknown
- 1988-11-22 KR KR1019880015383A patent/KR910005887B1/ko not_active IP Right Cessation
- 1988-11-22 JP JP63295890A patent/JPH02111731A/ja active Pending
- 1988-11-23 AU AU25824/88A patent/AU617380B2/en not_active Ceased
- 1988-11-23 PT PT89062A patent/PT89062B/pt active IP Right Grant
-
1992
- 1992-11-12 GR GR920402021T patent/GR3006211T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
AU2582488A (en) | 1989-05-25 |
NO885199L (no) | 1989-05-24 |
NO885199D0 (no) | 1988-11-22 |
NZ226955A (en) | 1991-11-26 |
US4952394A (en) | 1990-08-28 |
KR910005887B1 (ko) | 1991-08-06 |
AU617380B2 (en) | 1991-11-28 |
NO169958B (no) | 1992-05-18 |
FI885361A0 (fi) | 1988-11-18 |
FI885361A (fi) | 1989-05-24 |
EP0317957B1 (en) | 1992-11-04 |
JPH02111731A (ja) | 1990-04-24 |
EP0317957A3 (en) | 1989-07-05 |
ATE81986T1 (de) | 1992-11-15 |
GR3006211T3 (ko) | 1993-06-21 |
PT89062A (pt) | 1989-11-30 |
ZA886811B (en) | 1989-07-26 |
IL88428A0 (en) | 1989-06-30 |
DK651088A (da) | 1989-05-24 |
NO169958C (no) | 1992-08-26 |
CA1303524C (en) | 1992-06-16 |
DE3875700D1 (de) | 1992-12-10 |
EP0317957A2 (en) | 1989-05-31 |
DK651088D0 (da) | 1988-11-22 |
DE3875700T2 (de) | 1993-03-18 |
PT89062B (pt) | 1993-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR890007724A (ko) | 약물-모노클로날 항체 결합체 | |
CA2495795A1 (en) | Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs | |
RU95112841A (ru) | Полимерный конъюгат, способ его получения, производная 20-0-ациламинокамптотецина и способ ее получения, фармацевтическая композиция | |
DK1492526T3 (da) | Konjugerede prodrugs af CC-1065-analoger | |
KR900002804A (ko) | 세포독성 약물 결합체 및 이의 제조방법 | |
CA2437983A1 (en) | Transporters comprising spaced arginine moieties | |
KR920701200A (ko) | 신규의 4h-3,1-벤조옥사진-4-온 유도체 | |
CY1112527T1 (el) | Συνθεσεις που περιεχουν αμιοdαrονε και sulfoalkyl ether cyclodextrin | |
WO2002088172B1 (en) | Pentapeptide compounds and uses related thereto | |
CA2494049A1 (en) | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof | |
DE60303961D1 (de) | Modifizierte saccharide, deren konjugate sowie deren herstellung | |
ATE416186T1 (de) | Phenylethylenamin-derivate | |
FR2765478B1 (fr) | Nouvelles compositions cosmetiques comprenant un polymere filmogene | |
TR200101663T2 (tr) | Pro-kollajen c-proteinaz inhibitörleri | |
FI952141A (fi) | Molekyylimerkintä käyttäen 2-hydraninopyridiinijohdannaisia | |
KR910020034A (ko) | 내인성 신경 전달 물질의 유도체, 이들의 염, 이들을 함유하는 조성물, 이들의 제조 방법 및 용도 | |
PT96226A (pt) | Processo para a preparacao de derivados morfolinilicos de doxorubicina e de composicoes farmaceuticas que os contem | |
KR880011112A (ko) | 벤즈아제핀 설폰아미드 화합물 | |
DK0696585T3 (da) | Nyt bisoxadiazolidinderivat | |
KR910004557A (ko) | 2,4,6-치환 페놀 유도체 | |
CA2217026A1 (en) | New antiviral substituted pyrimidinedione homocarbocyclic nucleoside derivatives and methods for the preparation thereof and compositions containing the same as active ingredients | |
DE69125707D1 (de) | Anthracyclinkonjugate | |
FI940011A0 (fi) | Mono- ja bis-alkyyliaminoantrasykliinit | |
IE800912L (en) | Bis(4-demethoxydaunorubicin) dihydrazones | |
KR910000638A (ko) | 피롤카르복시산 유도체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
G160 | Decision to publish patent application | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
LAPS | Lapse due to unpaid annual fee |